+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients



Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients



Clinical Therapeutics 19(3): 471-480



This multicenter, open-label, third-party-masked trial compared the efficacy and safety of itraconazole oral solution (200 mg once daily) and clotrimazole troches (10 mg five times daily) in a population of immunocompromised subjects composed primarily of patients with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). Patients were treated for 14 days; patients who exhibited a clinical response were followed up for an additional month to document the occurrence of relapse. Efficacy was judged by changes from baseline in symptoms of oropharyngeal candidiasis (erythema, soreness/burning), extent of oral lesions, and the presence/absence of Candida species on fungal culture. A total of 162 patients were randomized, and 149 were evaluated for efficacy. The percentage of patients with negative cultures at the end of treatment was significantly greater in the itraconazole group than in the clotrimazole group (60% vs 32%, respectively). Negative culture plus clinical response was achieved in significantly more itraconazole-treated patients (53%) than clotrimazole-treated patients (30%); results were similar in the subgroup of patients with HIV/AIDS. Both drugs were well tolerated, with the most frequently reported adverse events for both agents involving the gastrointestinal system. In conclusion, systemic therapy with itraconazole oral solution is efficacious and well tolerated in immunocompromised patients, including those with HIV/AIDS, when administered once daily for 14 days for the treatment of oral candidiasis.

(PDF emailed within 0-6 h: $19.90)

Accession: 003186212

Download citation: RISBibTeXText

PMID: 9220211

DOI: 10.1016/s0149-2918(97)80131-2


Related references

Clotrimazole troches vs oral nystatin for oropharyngeal candidiasis. JAMA 259(10): 1497-1497, 1988

Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. Journal of Acquired Immune Deficiency Syndromes 6(12): 1311-1316, 1993

Itraconazole oral solution versus fluconazole treatment of oropharyngeal candidiasis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35(0): 244, 1995

Comparison of the efficacy of a novel sustained release clotrimazole varnish and clotrimazole troches for the treatment of oral candidiasis. Clinical Oral Investigations 19(2): 467-473, 2016

A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. Use in prophylaxis of oropharyngeal candidiasis. JAMA 258(18): 2553-2555, 1987

Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. Aids Research and Human Retroviruses 15(16): 1413-1417, 1999

Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrobial Agents and ChemoTherapy 34(11): 2267-2268, 1990

Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients. Brazilian Journal of Infectious Diseases 5(2): 60-66, 2001

A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clinical Infectious Diseases 26(6): 1368-1373, 1998

Treatment of chronic oral candidiasis with clotrimazole troches. A controlled clinical trial. New England Journal of Medicine 299(22): 1201-1203, 1978

Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. American Journal of Medicine 104(1): 33-39, 1998

Itraconazole oral solution for the treatment of oropharyngeal candidiasis Results of two randomized, blinded studies. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS Eleventh International Conference on AIDS, Vol One One world: One hope : 17, 1996

Prophylaxis of oral candidiasis with clotrimazole troches. Archives of Internal Medicine 144(2): 290-293, 1984

Randomized study of fluconazole oral solution versus amphotericin B oral solution in oropharyngeal candidiasis in elderly patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 490, 1998

Clotrimazole troches: a new therapeutic approach to oral candidiasis. Cutis 17(2): 277-280, 1976